生物技术公司Ocugen宣布,其针对广谱视网膜色素变性的新型修饰基因疗法Ocu400,已完成三期临床试验"Limelight"的患者招募工作。该疗法通过基因修饰技术靶向治疗多种基因突变导致的视网膜色素变性,有望为这类遗传性眼病患者提供新的治疗选择。
生物技术公司Ocugen宣布,其针对广谱视网膜色素变性的新型修饰基因疗法Ocu400,已完成三期临床试验"Limelight"的患者招募工作。该疗法通过基因修饰技术靶向治疗多种基因突变导致的视网膜色素变性,有望为这类遗传性眼病患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.